Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dr Reddys Laboratories (RDY) EBITDA (2016 - 2025)

Historic EBITDA for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $159.9 million.

  • Dr Reddys Laboratories' EBITDA rose 76695.21% to $159.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $375.0 million, marking a year-over-year increase of 216101.19%. This contributed to the annual value of $842.0 million for FY2025, which is 1072521.75% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its EBITDA stood at $159.9 million for Q4 2025, which was up 76695.21% from $203.8 million recorded in Q1 2025.
  • In the past 5 years, Dr Reddys Laboratories' EBITDA ranged from a high of $217.5 million in Q2 2023 and a low of -$24.0 million during Q4 2024
  • Its 5-year average for EBITDA is $122.4 million, with a median of $150.8 million in 2022.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 30120.86% in 2024, then surged by 313837.52% in 2025.
  • Over the past 5 years, Dr Reddys Laboratories' EBITDA (Quarter) stood at $19.0 million in 2021, then surged by 693.62% to $150.8 million in 2022, then crashed by 92.1% to $11.9 million in 2023, then tumbled by 301.21% to -$24.0 million in 2024, then skyrocketed by 766.95% to $159.9 million in 2025.
  • Its last three reported values are $159.9 million in Q4 2025, $203.8 million for Q1 2025, and -$24.0 million during Q4 2024.